Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 36Terminated 16Unknown 4Withdrawn 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Melanoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Panobinostat × Clear all
NCT03982134 2019-10-04

PDR001 + Panobinostat for Melanoma and NSCLC

University of Iowa

Phase 1 Withdrawn
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT01160731 2014-12-31

Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Cancer Trials Ireland

Phase 1 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡